Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice

Hepatitis Monthly

Volumn 11, Issue 8, 2011, Pages 620-628

  Chen, Jian Hua ^a   Yu, Yong Sheng ^a   Liu, Hong Hong ^a   Chen, Xiao Hua ^a   Xi, Min ^a   Zang, Guo Qing ^a   Tang, Zheng Hao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

DNA vaccine; Hepatitis B core antigen; Ubiquitin

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG CONJUGATION; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE DELIVERY SYSTEM; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN;

EID: 80052557924     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.689     Document Type: Article

References (46)

1. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):1-21, vii.
2. Cova L. DNA vaccine: a promising new approach for chronic hepatitis B therapy. Future Virol. 2007;2(5):421-4.
3. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, et al. Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol. 2000;74(24):11598-607.
4. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998;4(4):397-402.
5. Huang ZH, Zhuang H, Lu S, Guo RH, Xu GM, Cai J, et al. Humoral and cellular immunogenecity of DNA vaccine based on hepatitis B core gene in rhesus monkeys. World J Gastroenterol. 2001;7(1):102-6.
6. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5-to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon. 2010;10(1):17-21.
7. Moingeon P, Almond J, de Wilde M. Therapeutic vaccines against infectious diseases. Curr Opin Microbiol. 2003;6(5):462-71.
8. Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sallberg M, et al. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol. 2001;75(14):6359-66.
9. Tang TJ, de Man RA, Kusters JG, Kwekkeboom J, Hop WC, van der Molen RG, et al. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients. J Med Virol. 2004;72(2):215-22.
10. Lu M, Hilken G, Kruppenbacher J, Kemper T, Schirmbeck R, Reimann J, et al. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol. 1999;73(1):281-9.
11. Kuhober A, Pudollek HP, Reifenberg K, Chisari FV, Schlicht HJ, Reimann J, et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol. 1996;156(10):3687-95.
12. Miche ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;54(6):1286-96.
13. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol. 2002;66(4):452-60.
14. Qing Y, Chen M, Zhao J, Hu H, Xu H, Ling N, et al. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBVtransgenic mice. Vaccine. 2010;28(26):4301-7.
15. Zhou C, Peng G, Jin X, Tang J, Chen Z. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine. Clin Immunol. 2010;137(2):190-8.
16. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis. 2002;2(1):43-50.
17. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4(1):25-36.
18. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68-76.
19. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol. 2002;80:1-70.
20. Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, Chiba T, et al. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene Ther. 2005;12(13):1049-57.
21. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol. 2004;16(1):76-81.
22. Wang QM, Kang L, Wang XH. Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis. Microbiol Immunol. 2009;53(7):384-90.
23. Woo SK, Lee JI, Park IK, Yoo YJ, Cho CM, Kang MS, et al. Multiple ubiquitin C-terminal hydrolases from chick skeletal muscle. J Biol Chem. 1995;270(32):18766-73.
24. Yan J, Liu X, Wang Y, Jiang X, Liu H, Wang M, et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med. 2007;9(2):107-21.
25. Chen X, Yu Y, Pan Q, Tang Z, Han J, Zang G. Enhancement of cytotoxic T lymphocyte activity by dendritic cells loaded with Tat-protein transduction domain-fused hepatitis B virus core antigen. Acta Biochim Biophys Sin (Shanghai). 2008;40(12):996-1004.
26. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest. 1996;97(7):1655-65.
27. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006;87(Pt 6):1439-49.
28. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997;158(3):1231-7.
29. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol. 1999;162(8):4790-5.
30. Sijts A, Zaiss D, Kloetzel PM. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med. 2001;1(6):665-76.
31. Chen X, Lai J, Pan Q, Tang Z, Yu Y, Zang G. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Vaccine. 2010;28(23):3913-9.
32. Wang J, Dong S, Liu C, Wang W, Sun S, Gu J, et al. beta-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen. J Biomed Biotechnol. 2010; [Epub ahead of print].
33. Gao G, Luo H. The ubiquitin-proteasome pathway in viral infections. Can J Physiol Pharmacol. 2006;84(1):5-14.
34. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458(7237):430-7.
35. Kessler BM, Glas R, Ploegh HL. MHC class I antigen processing regulated by cytosolic proteolysis--short cuts that alter peptide generation. Mol Immunol. 2002;39(3-4):171-9.
36. Wu Y, Kipps TJ. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol. 1997;159(12):6037-43.
37. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol. 2008;8(7):501-11.
38. Mogk A, Schmidt R, Bukau B. The N-end rule pathway for regulated proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol. 2007;17(4):165-72.
39. Delogu G, Howard A, Collins FM, Morris SL. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun. 2000;68(6):3097-102.
40. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol. 1997;71(11):8497-503.
41. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-29.
42. Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T, Takeshima T, et al. Critical role of the Th1/Tc1 circuit for the generation of tumorspecific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 2003;94(10):924-8.
43. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol. 1997;71(3):2192-201.
44. Brandsma JL, Shlyankevich M, Zelterman D, Su Y. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine. 2007;25(33):6158-63.
45. Sharma A, Madhubala R. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimonysusceptible and-resistant strains of Leishmania donovani. J Immunol. 2009;183(12):7719-31.
46. Vidalin O, Tanaka E, Spengler U, Trepo C, Inchauspe G. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol. 1999;18(8):611-21.